地舒单抗临床应用安全性的思考

被引：7

作者：

牛晓辉

刘巍峰

机构：

[1] 北京积水潭医院骨肿瘤科

来源：

中国骨与关节杂志 | 2018年 / 7卷 / 09期

关键词：

骨巨细胞瘤; RANK-RANKL; 安全; 复发; 地舒单抗;

D O I：

暂无

中图分类号：

R969 [临床药理学];

学科分类号：

100706 [药理学];

摘要：

<正>一、概述地舒单抗（Denosumab）是首个被用于抑制核因子k B受体激活剂（receptor activator of nuclear factor-k B ligand,RANKL）及骨质疏松、其它骨骼疾病的药物。RANKL与其在破骨细胞前体上的受体RANK结合是破骨细胞增殖、成熟、活化和存活的必要条件[1]。骨保护素（osteoprotegerin,OPG）是RANK的一种可溶形

引用

页码：641 / 645

页数：5

共 20 条

[1]

Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage [J].

Errani, Costantino ;

Tsukamoto, Shinji ;

Leone, Giulio ;

Righi, Alberto ;

Akahane, Manabu ;

Tanaka, Yasuhito ;

Donati, Davide Maria .

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2018, 100 (06) :496-504

[2]

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study [J].

Raje, Noopur ;

Terpos, Evangelos ;

Willenbacher, Wolfgang ;

Shimizu, Kazuyuki ;

Garcia-Sanz, Ramon ;

Durie, Brian ;

Legiec, Wojciech ;

Krejci, Marta ;

Laribi, Kamel ;

Zhu, Li ;

Cheng, Paul ;

Warner, Douglas ;

Roodman, G. David .

LANCET ONCOLOGY, 2018, 19 (03) :370-381

[3]

How safe and effective is denosumab for bone giant cell tumour? [J].

Errani, Costantino ;

Tsukamoto, Shinji ;

Mavrogenis, Andreas F. .

INTERNATIONAL ORTHOPAEDICS, 2017, 41 (11) :2397-2400

[4]

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries [J].

Body, Jean-Jacques ;

Gatta, Francesca ;

De Cock, Erwin ;

Tao, Sunning ;

Kritikou, Persefoni ;

Wimberger, Pauline ;

Mebis, Jeroen ;

Peeters, Marc ;

Pedrazzoli, Paolo ;

Caraceni, Augusto ;

Adamo, Vincenzo ;

Hechmati, Guy .

SUPPORTIVE CARE IN CANCER, 2017, 25 (09) :2823-2832

[5]

Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.[J].Frank Traub;Janith Singh;Brendan C. Dickson;Stephanie Leung;Rakesh Mohankumar;Martin E. Blackstein;Albiruni R. Razak;Anthony M. Griffin;Peter C. Ferguson;Jay S. Wunder.European Journal of Cancer.2016,

[6]

Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone [J].

Rutkowski, Piotr ;

Ferrari, Stefano ;

Grimer, Robert J. ;

Stalley, Paul D. ;

Dijkstra, Sander P. D. ;

Pienkowski, Andrzej ;

Vaz, Gualter ;

Wunder, Jay S. ;

Seeger, Leanne L. ;

Feng, Amy ;

Roberts, Zachary J. ;

Bach, Bruce A. .

ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (09) :2860-2868

[7]

Giant-cell tumor of bone: treatment options and role of denosumab.[J].Singh AS;Chawla NS;Chawla SP.Biologics : Targets & Therapy.2015, default

[8]

Giant cell tumors of the spine: has denosumab changed the treatment paradigm? [J].

Goldschlager, Tony ;

Dea, Nicolas ;

Boyd, Michael ;

Reynolds, Jeremy ;

Patel, Shreyaskumar ;

Rhines, Laurence D. ;

Mendel, Ehud ;

Pacheco, Marina ;

Ramos, Edwin ;

Mattei, Tobias A. ;

Fisher, Charles G. .

JOURNAL OF NEUROSURGERY-SPINE, 2015, 22 (05) :526-533

[9]

A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab [J].

Mak, Isabella W. Y. ;

Evaniew, Nathan ;

Popovic, Snezana ;

Tozer, Richard ;

Ghert, Michelle .

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2014, 96A (15) :e127(1)

[10]

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study [J].

Martin-Broto, Javier ;

Cleeland, Charles S. ;

Glare, Paul A. ;

Engellau, Jacob ;

Skubitz, Keith M. ;

Blum, Ronald H. ;

Ganjoo, Kristin N. ;

Staddon, Arthur ;

Dominkus, Martin ;

Feng, Amy ;

Qian, Yi ;

Braun, Ada ;

Jacobs, Ira ;

Chung, Karen ;

Atchison, Carolyn .

ACTA ONCOLOGICA, 2014, 53 (09) :1173-1179

← 1 2 →